{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:37:44Z","timestamp":1783039064766,"version":"3.54.6"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The data on lipid profile differences between primary aldosteronism (PA) and essential hypertension (EH) patients are inconsistent and inconclusive. Most studies reported lower levels of lipid profiles in PA than in EH. This meta-analysis aimed to explore differences in serum lipid profiles including triglyceride (TG), total cholesterol (TC), LDL and HDL levels in PA patients and EH patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A search of published studies was performed using <jats:italic>PubMed<\/jats:italic>, <jats:italic>Embase<\/jats:italic> and <jats:italic>Scopus<\/jats:italic> databases from their inception through August 2022. Thirty studies involving 11,175 patients were identified. Inclusion criteria included 1) observational studies which contained data on any of the lipid profiles of interest (TG, TC, LDL and HDL) which could be acquired from baseline data or the outcomes, 2) data which should be compared between adult PA and EH patients and 3) the use of appropriate methods to diagnose PA. Standardized mean difference (SMD) with a 95% confidence interval (95% CI) was calculated to assess effect size by using STATA program version 15.0. Risk of bias was assessed by Joanna Briggs Institute (JBI) Critical Appraisal Tools for cross-sectional, cohort and case-control studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Levels of the lipid parameters TG (SMD \u2212\u20090.16\u2009mmol\/L; 95%CI (\u2212\u20090.25, \u2212\u20090.07)), TC (SMD \u2212\u20090.30\u2009mmol\/L; 95%CI (\u2212\u20090.41, \u2212\u20090.19)) and LDL (SMD \u2212\u20090.17\u2009mmol\/L; 95%CI (\u2212\u20090.27, \u2212\u20090.08)) were significantly lower in PA than in EH patients. There was no statistically significant difference in HDL between PA and EH patients (SMD \u2212\u20090.08\u2009mmol\/L; 96%CI (\u2212\u20090.23,0.07)). High levels of heterogeneity for TG, TC, HDL and LDL were observed in all studies. Risk of bias among the studies was low to moderate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Lower levels of TG, TC and LDL were observed in PA than in EH patients. Further study should be conducted to address the underlying mechanisms of lipid alteration in PA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01135-y","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T09:02:56Z","timestamp":1661936576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The differences of serum lipid profiles between primary aldosteronism and essential hypertension: a meta-analysis and systematic review"],"prefix":"10.1186","volume":"22","author":[{"given":"Worapaka","family":"Manosroi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitchaporn","family":"Phudphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pichitchai","family":"Atthakomol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattabhorn","family":"Phimphilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"1135_CR1","doi-asserted-by":"publisher","first-page":"162804","DOI":"10.4061\/2011\/162804","volume":"2011","author":"RM Fagugli","year":"2011","unstructured":"Fagugli RM, Taglioni C. Changes in the perceived epidemiology of primary hyperaldosteronism. Int J Hypertens. 2011;2011:162804.","journal-title":"Int J Hypertens"},{"issue":"5","key":"1135_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1135_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ajh.2010.169","volume":"23","author":"LA Sechi","year":"2010","unstructured":"Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary Aldosteronism: outcomes after treatment. Am J Hypertens. 2010;23(12):1253\u201360.","journal-title":"Am J Hypertens"},{"issue":"2","key":"1135_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/HYPERTENSIONAHA.107.095489","volume":"51","author":"NJ Brown","year":"2008","unstructured":"Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51(2):161\u20137.","journal-title":"Hypertension"},{"issue":"2","key":"1135_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","volume":"48","author":"M Bochud","year":"2006","unstructured":"Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48(2):239\u201345.","journal-title":"Hypertension"},{"key":"1135_CR6","doi-asserted-by":"publisher","first-page":"4128174","DOI":"10.1155\/2018\/4128174","volume":"2018","author":"M Hannich","year":"2018","unstructured":"Hannich M, Wallaschofski H, Nauck M, Reincke M, Adolf C, V\u00f6lzke H, et al. Physiological aldosterone concentrations are associated with alterations of lipid metabolism: observations from the general population. Int J Endocrinol. 2018;2018:4128174.","journal-title":"Int J Endocrinol"},{"issue":"1","key":"1135_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1161\/01.HYP.25.1.30","volume":"25","author":"TL Goodfriend","year":"1995","unstructured":"Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995;25(1):30\u20136.","journal-title":"Hypertension"},{"issue":"1","key":"1135_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12020-016-0983-9","volume":"54","author":"C Adolf","year":"2016","unstructured":"Adolf C, Asbach E, Dietz AS, Lang K, Hahner S, Quinkler M, et al. Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine. 2016;54(1):198\u2013205.","journal-title":"Endocrine"},{"issue":"1","key":"1135_CR9","first-page":"e116","volume":"29","author":"AS Shihab","year":"2022","unstructured":"Shihab AS, Hamdi MA, Jumaa AM, Marbut MM, Jwad SK. Dyslipidemia and other parameters in women with pregnancy induced hypertension. J Popul Ther Clin Pharmacol. 2022;29(1):e116\u201321.","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"4","key":"1135_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3803\/EnM.2021.1012","volume":"36","author":"SJ Moon","year":"2021","unstructured":"Moon SJ, Jang HN, Kim JH, Moon MK. Lipid profiles in primary Aldosteronism compared with essential hypertension: propensity-score matching study. Endocrinol Metab (Seoul). 2021;36(4):885\u201394.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"1135_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.numecd.2013.09.009","volume":"24","author":"F Turchi","year":"2014","unstructured":"Turchi F, Ronconi V, di Tizio V, Ceccoli L, Boscaro M, Giacchetti G. Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment. Nutr Metab Cardiovasc Dis. 2014;24(5):476\u201382.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"1135_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/cen.13891","volume":"90","author":"AMA Berends","year":"2019","unstructured":"Berends AMA, Buitenwerf E, Gruppen EG, Sluiter WJ, Bakker SJL, Connelly MA, et al. Primary aldosteronism is associated with decreased low-density and high-density lipoprotein particle concentrations and increased GlycA, a pro-inflammatory glycoprotein biomarker. Clin Endocrinol. 2019;90(1):79\u201387.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"1135_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension. 2012;60(3):618\u201324.","journal-title":"Hypertension"},{"issue":"4","key":"1135_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1161\/HYPERTENSIONAHA.108.122002","volume":"53","author":"J Matrozova","year":"2009","unstructured":"Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2009;53(4):605\u201310.","journal-title":"Hypertension"},{"issue":"14","key":"1135_CR15","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary Aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1135_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.amjhyper.2007.03.012","volume":"20","author":"F Fallo","year":"2007","unstructured":"Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, et al. Adiponectin and insulin sensitivity in primary Aldosteronism. Am J Hypertens. 2007;20(8):855\u201361.","journal-title":"Am J Hypertens"},{"key":"1135_CR17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.","journal-title":"Bmj"},{"issue":"1","key":"1135_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"issue":"11","key":"1135_CR19","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1503\/cmaj.1031981","volume":"171","author":"T McGinn","year":"2004","unstructured":"McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, for GG. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). Can Med Assoc J. 2004;171(11):1369\u201373.","journal-title":"Can Med Assoc J"},{"key":"1135_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3389\/fendo.2020.00493","volume":"11","author":"S Rangaswamaiah","year":"2020","unstructured":"Rangaswamaiah S, Gangathimmaiah V, Nordenstrom A, Falhammar H. Bone mineral density in adults with congenital adrenal hyperplasia: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020;11:493.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1135_CR21","doi-asserted-by":"publisher","first-page":"e13048","DOI":"10.1111\/acel.13048","volume":"18","author":"AA Johnson","year":"2019","unstructured":"Johnson AA, Stolzing A. The role of lipid metabolism in aging, lifespan regulation, and age-related disease. Aging Cell. 2019;18(6):e13048.","journal-title":"Aging Cell"},{"issue":"14","key":"1135_CR22","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1001\/jama.294.14.1773","volume":"294","author":"MD Carroll","year":"2005","unstructured":"Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. Jama. 2005;294(14):1773\u201381.","journal-title":"Jama"},{"issue":"3","key":"1135_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jacc.2008.09.041","volume":"53","author":"G Karthikeyan","year":"2009","unstructured":"Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART study. J Am Coll Cardiol. 2009;53(3):244\u201353.","journal-title":"J Am Coll Cardiol"},{"issue":"s8","key":"1135_CR24","doi-asserted-by":"publisher","first-page":"S681","DOI":"10.1046\/j.1440-6047.11.s8.5.x","volume":"11","author":"RC Weisell","year":"2002","unstructured":"Weisell RC. Body mass index as an indicator of obesity. Asia Pac J Clin Nutr. 2002;11(s8):S681\u20134.","journal-title":"Asia Pac J Clin Nutr"},{"issue":"3","key":"1135_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.12669\/pjms.35.3.7","volume":"35","author":"A Hussain","year":"2019","unstructured":"Hussain A, Ali I, Kaleem WA, Yasmeen F. Correlation between body mass index and lipid profile in patients with type 2 diabetes attending a tertiary care hospital in Peshawar. Pak J Med Sci. 2019;35(3):591\u20137.","journal-title":"Pak J Med Sci"},{"issue":"3","key":"1135_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/09735070.2017.1335109","volume":"11","author":"G Kaur","year":"2017","unstructured":"Kaur G, Sudhera N, Singh K, Singh G, Bassi DK. Effect of fasting blood glucose (FBG) on lipid metabolism and gender differences in the pattern of dyslipidemia in adults with type 2 diabetes in northern India. Stud Ethno-Med. 2017;11(3):209\u201315.","journal-title":"Stud Ethno-Med"},{"key":"1135_CR27","volume-title":"JBI manual for evidence synthesis JBI","author":"SMZ Moola","year":"2020","unstructured":"Moola SMZ, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, et al. Mu P-F chapter 7: systematic reviews of etiology and risk. In: Aromataris EMZ, editor. JBI manual for evidence synthesis JBI; 2020."},{"key":"1135_CR28","volume-title":"GRADE handbook for grading quality of evidence and strength of recommendations updated October (2013) the GRADE working group (2013)","author":"HBJ Sch\u00fcnemann","year":"2013","unstructured":"Sch\u00fcnemann HBJ, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations updated October (2013) the GRADE working group (2013); 2013."},{"issue":"9","key":"1135_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.amjhyper.2006.02.002","volume":"19","author":"B Strauch","year":"2006","unstructured":"Strauch B, Petr\u00e1k O, Wichterle D, Zelinka T, Holaj R, Widimsk\u00fd J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens. 2006;19(9):909\u201314.","journal-title":"Am J Hypertens"},{"issue":"2","key":"1135_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1135_CR31","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91(9):3457\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1135_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.numecd.2009.03.007","volume":"20","author":"V Ronconi","year":"2010","unstructured":"Ronconi V, Turchi F, Rilli S, Di Mattia D, Agostinelli L, Boscaro M, et al. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutr Metab Cardiovasc Dis. 2010;20(2):93\u2013100.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10","key":"1135_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/jhh.2010.65","volume":"24","author":"Z Soml\u00f3ov\u00e1","year":"2010","unstructured":"Soml\u00f3ov\u00e1 Z, Widimsk\u00fd J Jr, Rosa J, Wichterle D, Strauch B, Petr\u00e1k O, et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J Hum Hypertens. 2010;24(10):625\u201330.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"1135_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ajh.2009.206","volume":"23","author":"F Fallo","year":"2010","unstructured":"Fallo F, Dalla Pozza A, Tecchio M, Tona F, Sonino N, Ermani M, et al. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. Am J Hypertens. 2010;23(1):2\u20135.","journal-title":"Am J Hypertens"},{"issue":"10","key":"1135_CR35","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1097\/HJH.0b013e32833d0177","volume":"28","author":"CB Stehr","year":"2010","unstructured":"Stehr CB, Mellado R, Ocaranza MP, Carvajal CA, Mosso L, Becerra E, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens. 2010;28(10):2120\u20136.","journal-title":"J Hypertens"},{"issue":"5","key":"1135_CR36","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1210\/jc.2009-2204","volume":"95","author":"G Iacobellis","year":"2010","unstructured":"Iacobellis G, Petramala L, Cotesta D, Pergolini M, Zinnamosca L, Cianci R, et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab. 2010;95(5):2391\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1135_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","volume":"62","author":"S Savard","year":"2013","unstructured":"Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331\u20136.","journal-title":"Hypertension"},{"issue":"5","key":"1135_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5603\/EP.2013.0019","volume":"64","author":"A Prejbisz","year":"2013","unstructured":"Prejbisz A, Florczak E, Klisiewicz A, Dobrowolski P, Janaszek-Sitkowska H, Biele\u0144 P, et al. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension. Endokrynol Pol. 2013;64(5):363\u20137.","journal-title":"Endokrynol Pol"},{"issue":"12","key":"1135_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/jhh.2014.11","volume":"28","author":"G Liu","year":"2014","unstructured":"Liu G, Yin GS, Tang JY, Ma DJ, Ru J, Huang XH. Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage. J Hum Hypertens. 2014;28(12):711\u20135.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"1135_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/joim.13115","volume":"289","author":"MK Choudhary","year":"2021","unstructured":"Choudhary MK, V\u00e4rri E, Matikainen N, Koskela J, Tikkakoski AJ, K\u00e4h\u00f6nen M, et al. Primary aldosteronism: higher volume load, cardiac output and arterial stiffness than in essential hypertension. J Intern Med. 2021;289(1):29\u201341.","journal-title":"J Intern Med"},{"issue":"3","key":"1135_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/hr.2016.127","volume":"40","author":"Y Yang","year":"2017","unstructured":"Yang Y, Zhu LM, Xu JZ, Tang XF, Gao PJ. Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography. Hypertens Res. 2017;40(3):243\u201350.","journal-title":"Hypertens Res"},{"issue":"7","key":"1135_CR42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/10641963.2016.1182176","volume":"38","author":"D Watanabe","year":"2016","unstructured":"Watanabe D, Yatabe M, Ichihara A. Evaluation of insulin sensitivity and secretion in primary aldosteronism. Clin Exp Hypertens. 2016;38(7):613\u20137.","journal-title":"Clin Exp Hypertens"},{"key":"1135_CR43","first-page":"4828402","volume":"2019","author":"H Li","year":"2019","unstructured":"Li H, Liu J, Liu J, Liu L, Huang M, Wei G, et al. The association between a 24-hour blood pressure pattern and circadian change in plasma aldosterone concentration for patients with aldosterone-producing adenoma. Int J Endocrinol. 2019;2019:4828402.","journal-title":"Int J Endocrinol"},{"key":"1135_CR44","doi-asserted-by":"crossref","unstructured":"Er LK, Lin MC, Tsai YC, Hsiao JK, Yang CY, Chang CC, et al. Association of visceral adiposity and clinical outcome among patients with aldosterone producing adenoma. BMJ Open Diabetes Res Care. 2020;8(1)1-8.","DOI":"10.1136\/bmjdrc-2019-001153"},{"issue":"2","key":"1135_CR45","first-page":"240","volume":"39","author":"N Vuja\u010di\u0107","year":"2020","unstructured":"Vuja\u010di\u0107 N, Paunovi\u0107 I, Dikli\u0107 A, \u017divaljevi\u0107 V, Slijep\u010devi\u0107 N, Kalezi\u0107 N, et al. Biochemical and clinical characteristics of patients with primary aldosteronism: single Centre experience. J Med Biochem. 2020;39(2):240\u20138.","journal-title":"J Med Biochem"},{"issue":"1","key":"1135_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12902-020-00654-w","volume":"20","author":"W Manosroi","year":"2020","unstructured":"Manosroi W, Atthakomol P. High body fat percentage is associated with primary aldosteronism: a cross-sectional study. BMC Endocr Disord. 2020;20(1):175.","journal-title":"BMC Endocr Disord"},{"key":"1135_CR47","doi-asserted-by":"publisher","first-page":"547356","DOI":"10.3389\/fendo.2020.547356","volume":"11","author":"SL Zhang","year":"2020","unstructured":"Zhang SL, Gao JW, Guo Y, Feng QL, Tang JY, Yan L, et al. Associations between metabolic profiles and target-organ damage in Chinese individuals with primary Aldosteronism. Front Endocrinol (Lausanne). 2020;11:547356.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1135_CR48","doi-asserted-by":"crossref","unstructured":"Hu Y, Zhang J, Liu W, Su X. Determining the prevalence of primary Aldosteronism in patients with new-onset type 2 diabetes and hypertension. J Clin Endocrinol Metab. 2020;105(4)1079-85.","DOI":"10.1210\/clinem\/dgz293"},{"issue":"9","key":"1135_CR49","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/HJH.0000000000002441","volume":"38","author":"M Parasiliti-Caprino","year":"2020","unstructured":"Parasiliti-Caprino M, Lopez C, Prencipe N, Lucatello B, Settanni F, Giraudo G, et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens. 2020;38(9):1841\u20138.","journal-title":"J Hypertens"},{"issue":"1","key":"1135_CR50","doi-asserted-by":"publisher","first-page":"147032032199949","DOI":"10.1177\/1470320321999491","volume":"22","author":"M Sang","year":"2021","unstructured":"Sang M, Fu Y, Wei C, Yang J, Qiu X, Ma J, et al. Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension. J Renin-Angiotensin-Aldosterone Syst. 2021;22(1):1470320321999491.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"issue":"2","key":"1135_CR51","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12020-021-02704-2","volume":"73","author":"M Fern\u00e1ndez-Arg\u00fceso","year":"2021","unstructured":"Fern\u00e1ndez-Arg\u00fceso M, Pascual-Corrales E, Bengoa Rojano N, Garc\u00eda Cano A, Jim\u00e9nez Mendiguch\u00eda L, Araujo-Castro M. Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study. Endocrine. 2021;73(2):439\u201346.","journal-title":"Endocrine"},{"key":"1135_CR52","first-page":"6685469","volume":"2021","author":"X Huang","year":"2021","unstructured":"Huang X, Yu S, Xiao H, Pei L, Chen Y, Chen W, et al. Comparison of clinical features between primary Aldosteronism and essential hypertension in Chinese patients: a case-control study. Int J Endocrinol. 2021;2021:6685469.","journal-title":"Int J Endocrinol"},{"issue":"11","key":"1135_CR53","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1161\/STROKEAHA.115.011164","volume":"46","author":"S Yaghi","year":"2015","unstructured":"Yaghi S, Elkind MSV. Lipids and cerebrovascular disease: research and practice. Stroke. 2015;46(11):3322\u20138.","journal-title":"Stroke"},{"issue":"26","key":"1135_CR54","doi-asserted-by":"publisher","first-page":"e15985","DOI":"10.1097\/MD.0000000000015985","volume":"98","author":"X Wu","year":"2019","unstructured":"Wu X, Yu J, Tian H. Cardiovascular risk in primary aldosteronism: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(26):e15985.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"1135_CR55","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.2337\/dc12-2562","volume":"36","author":"SK Musani","year":"2013","unstructured":"Musani SK, Vasan RS, Bidulescu A, Liu J, Xanthakis V, Sims M, et al. Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson heart study. Diabetes Care. 2013;36(10):3084\u201392.","journal-title":"Diabetes Care"},{"issue":"5","key":"1135_CR56","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1530\/EJE-10-1074","volume":"164","author":"A Hannemann","year":"2011","unstructured":"Hannemann A, Meisinger C, Bidlingmaier M, D\u00f6ring A, Thorand B, Heier M, et al. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol. 2011;164(5):751\u20138.","journal-title":"Eur J Endocrinol"},{"issue":"5 Pt 1","key":"1135_CR57","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.amjhyper.2004.12.005","volume":"18","author":"S Kathiresan","year":"2005","unstructured":"Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham heart study. Am J Hypertens. 2005;18(5 Pt 1):657\u201365.","journal-title":"Am J Hypertens"},{"issue":"9","key":"1135_CR58","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1096\/fj.06-7970com","volume":"21","author":"M Caprio","year":"2007","unstructured":"Caprio M, F\u00e8ve B, Cla\u00ebs A, Viengchareun S, Lomb\u00e8s M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007;21(9):2185\u201394.","journal-title":"FASEB J"},{"issue":"1","key":"1135_CR59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","volume":"90","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41\u201352.","journal-title":"Kidney Int"},{"issue":"5","key":"1135_CR60","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1681\/ASN.2004100878","volume":"16","author":"J Ribstein","year":"2005","unstructured":"Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005;16(5):1320\u20135.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1135_CR61","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1159\/000490686","volume":"43","author":"A \u0106wikli\u0144ska","year":"2018","unstructured":"\u0106wikli\u0144ska A, Cackowska M, Wieczorek E, Kr\u00f3l E, Kowalski R, Kuchta A, et al. Progression of chronic kidney disease affects HDL impact on lipoprotein lipase (LPL)-mediated VLDL lipolysis efficiency. Kidney Blood Press Res. 2018;43(3):970\u20138.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"1135_CR62","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jacl.2017.03.018","volume":"11","author":"E Buitenwerf","year":"2017","unstructured":"Buitenwerf E, Dullaart RPF, Muller Kobold AC, Links TP, Sluiter WJ, Connelly MA, et al. Cholesterol delivery to the adrenal glands estimated by adrenal venous sampling: an in vivo model to determine the contribution of circulating lipoproteins to steroidogenesis in humans. J Clin Lipidol. 2017;11(3):733\u20138.","journal-title":"J Clin Lipidol"},{"key":"1135_CR63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mam.2016.04.001","volume":"49","author":"S Maqdasy","year":"2016","unstructured":"Maqdasy S, Trousson A, Tauveron I, Volle DH, Baron S, Lobaccaro JM. Once and for all, LXR\u03b1 and LXR\u03b2 are gatekeepers of the endocrine system. Mol Asp Med. 2016;49:31\u201346.","journal-title":"Mol Asp Med"},{"issue":"6","key":"1135_CR64","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2165\/00002018-200124060-00003","volume":"24","author":"AK Mantel-Teeuwisse","year":"2001","unstructured":"Mantel-Teeuwisse AK, Kloosterman JM. Maitland-van der zee AH, Klungel OH, Porsius AJ, de Boer a: drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf. 2001;24(6):443\u201356.","journal-title":"Drug Saf"},{"issue":"3","key":"1135_CR65","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1055\/s-0031-1295412","volume":"44","author":"F Fallo","year":"2012","unstructured":"Fallo F, Pilon C, Urbanet R. Primary aldosteronism and metabolic syndrome. Horm Metab Res. 2012;44(3):208\u201314.","journal-title":"Horm Metab Res"},{"issue":"1","key":"1135_CR66","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.201304152","volume":"23","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Pan Y, Ma X, Yang H, Chang J, Hong L, et al. Elevated secretion of aldosterone increases TG\/HDL-C ratio and potentiates the ox-LDL-induced dysfunction of HUVEC. Cell J. 2021;23(1):61\u20139.","journal-title":"Cell J"},{"issue":"11","key":"1135_CR67","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/j.1742-1241.2007.01596.x","volume":"61","author":"M Rizzo","year":"2007","unstructured":"Rizzo M, Berneis K. Who needs to care about small, dense low-density lipoproteins? Int J Clin Pract. 2007;61(11):1949\u201356.","journal-title":"Int J Clin Pract"},{"issue":"9 Pt B","key":"1135_CR68","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1016\/j.bbadis.2018.05.012","volume":"1864","author":"M Rizzo","year":"2018","unstructured":"Rizzo M, Nikolic D, Patti AM, Mannina C, Montalto G, McAdams BS, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms. Biochim Biophys Acta Mol basis Dis. 2018;1864(9 Pt B):2814\u201321.","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"issue":"31","key":"1135_CR69","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.2174\/1381612819666131206103102","volume":"20","author":"N Abate","year":"2014","unstructured":"Abate N, Sallam HS, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. 2014;20(31):4961\u20139.","journal-title":"Curr Pharm Des"},{"key":"1135_CR70","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582(7810):73\u20137."},{"issue":"1","key":"1135_CR71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5551\/jat.RV16004","volume":"24","author":"R Naito","year":"2017","unstructured":"Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017;24(1):19\u201325.","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"1135_CR72","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1161\/HYPERTENSIONAHA.119.13922","volume":"75","author":"GK Adler","year":"2020","unstructured":"Adler GK, Murray GR, Turcu AF, Nian H, Yu C, Solorzano CC, et al. Primary Aldosteronism decreases insulin secretion and increases insulin clearance in humans. Hypertension. 2020;75(5):1251\u20139.","journal-title":"Hypertension"},{"issue":"3","key":"1135_CR73","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1055\/s-0031-1295459","volume":"44","author":"S Saha","year":"2012","unstructured":"Saha S, Willenberg HS, Bornstein SR, Graessler J, Kopprasch S. Diabetic lipoproteins and adrenal aldosterone synthesis--a possible pathophysiological link? Horm Metab Res. 2012;44(3):239\u201344.","journal-title":"Horm Metab Res"},{"issue":"2","key":"1135_CR74","doi-asserted-by":"publisher","first-page":"224","DOI":"10.4103\/jnsbm.jnsbm_53_21","volume":"12","author":"L Rerksuppaphol","year":"2021","unstructured":"Rerksuppaphol L, Rerksuppaphol S. Comparison of equations for the calculation of low-density lipoprotein cholesterol in Thai population. J Nat Sci Biol Med. 2021;12(2):224\u20139.","journal-title":"J Nat Sci Biol Med"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01135-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T10:05:23Z","timestamp":1661940323000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01135-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01135-y","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"assertion":[{"value":"7 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}